Stock · JBCHEPHARM · Healthcare
JBCHEPHARM share price target 2026
Support, resistance, the F&O structure and the BazaarBaazi Crack Score for JB Chemicals & Pharmaceuticals Limited, refreshed every end-of-day run. A systematic, data-only read on JB Chemicals & Pharmaceuticals Limited: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
The verdict
BazaarBaazi reads JBCHEPHARM as constructive with a Crack Score of 93/100 as of 21 Jul 2026.
BazaarBaaziSource & method
The scanner's readScanned · scanned 21 Jul 2026
Where JBCHEPHARM stands on the 500-name BazaarBaazi setup scanner: technicals, filed fundamentals and money flow read together, refreshed every run.
Scanned and scored this run, but the evidence is incomplete or conflicted. The engine fails closed to NO_TRADE.
Technical axis
100/100Fundamental axis
20/100Money flow
60/100Result pulse · Q4 FY26
20/100Technical evidence
price above 50DMA
price above 150DMA
price above 200DMA
50 > 150 > 200 DMA (clean stack)
uptrend frame (50 > 200 DMA)
50DMA rising
pulled back to a rising MA
orderly dip from highs
Red flags
above 200DMA (not a confirmed short-side trend)
profit collapse (-30.42% YoY)
weak filed result (score 20.0)
Relative valuation
P/E (TTM)
53.2P/E vs sector
+1.1%Sector percentile
53PEG
n/aScanner levels from the deterministic engine run of 2026-07-21, not a SEBI-registered recommendation and not investment advice. The fundamental axis reads the official filing: Q4 FY26 result.
Price target: support and resistanceComputed 21 Jul 2026
Support and resistance for JBCHEPHARM are read inside the latest show; no spot was printed in the most recent editorial note.
Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 20 Jul 2026.
These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the JBCHEPHARM chart, refreshed every end-of-day run.
The Crack Score, and how it is built93 / 100 · High conviction
The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for JBCHEPHARM, so the figure is a transparent signal rather than a vibe.
Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.
The F&O viewHorizon · swing
How the futures and options structure on JBCHEPHARM reads right now.
The editorial price read on JBCHEPHARM is bullish. Strike-level option inventory is unavailable, so the page withholds writer, wall and pin claims. Single-stock F&O on JBCHEPHARM can be thinner than index F&O, so the desk weights price and filed evidence over raw OI. This is not a derivatives trade recommendation.
Why it movedLatest editorial line
The most recent BazaarBaazi read on what is driving JBCHEPHARM.
Systematic read: a disclosed, data-only model on real 1-year price structure.
Read in Systematic Read on 20 Jul 2026. Why JBCHEPHARM moved, the living explainer, tracks every move on one URL.
Latest filed resultsQ4 FY26
JB Chemicals & Pharmaceuticals Limited's most recent quarter, parsed straight from the official NSE filing. Every figure links back to its primary source.
Result Pulse
20 / 100Revenue
Rs 904 crNet profit
Rs 101 crEPS (quarter)
Rs 6.35| Growth | YoY | QoQ |
|---|---|---|
| Revenue | -4.8% | -15.1% |
| Net profit | -30.4% | -48.8% |
| Net margin | +11.2% | |
Figures are the Q4 FY26 result for JB Chemicals & Pharmaceuticals Limited, parsed straight from the official NSE integrated filing and verified to the paisa. The EPS shown is for the quarter, not a trailing-twelve-month figure, so it is not a P/E input.
Earnings history, every filed quarter32 quarters on record
JB Chemicals & Pharmaceuticals Limited's official quarterly revenue, EPS and Result Pulse trail, every quarter the desk holds from the verified filings export, back to 30 Jun 2018. These are quarterly facts, not TTM valuation inputs.
JBCHEPHARM official result trail
32 quarters
Quarterly figures only: revenue, net profit and EPS are copied from official filings. EPS here is not trailing twelve month EPS and is not used for valuation.
| Quarter | Revenue | EPS | PAT YoY | Pulse | Source |
|---|---|---|---|---|---|
| Q4 FY26ended 31 Mar 2026 / Consolidated, audited | Rs 904 cr | Rs 6.35 | -30.4% | 20/100 | Filing |
| Q3 FY26ended 31 Dec 2025 / Consolidated, audited | Rs 1,065 cr | Rs 12.63 | n/a | 58/100 | Filing |
| Q2 FY26ended 30 Sep 2025 / Consolidated, audited | Rs 1,085 cr | Rs 13.29 | n/a | 58/100 | Filing |
| Q1 FY26ended 30 Jun 2025 / Consolidated, audited | Rs 1,094 cr | Rs 12.99 | n/a | 58/100 | Filing |
| Q4 FY25ended 31 Mar 2025 / Consolidated, audited | Rs 949 cr | Rs 9.36 | n/a | 58/100 | Filing |
| Q3 FY25ended 31 Dec 2024 / Consolidated, audited | Rs 963 cr | Rs 10.46 | n/a | n/a | Filing |
| Q2 FY25ended 30 Sep 2024 / Consolidated, audited | Rs 1,001 cr | Rs 11.24 | n/a | n/a | Filing |
| Q1 FY25ended 30 Jun 2024 / Consolidated, audited | Rs 1,004 cr | Rs 11.39 | n/a | n/a | Filing |
| Q4 FY24ended 31 Mar 2024 / Consolidated, audited | Rs 862 cr | Rs 8.22 | n/a | n/a | Filing |
| Q3 FY24ended 31 Dec 2023 / Consolidated, audited | Rs 845 cr | Rs 8.62 | n/a | n/a | Filing |
| Q2 FY24ended 30 Sep 2023 / Consolidated, audited | Rs 882 cr | Rs 9.72 | n/a | n/a | Filing |
| Q1 FY24ended 30 Jun 2023 / Consolidated, audited | Rs 896 cr | Rs 18.39 | n/a | n/a | Filing |
| Q4 FY23ended 31 Mar 2023 / Consolidated, audited | Rs 762 cr | Rs 11.33 | n/a | n/a | Filing |
| Q3 FY23ended 31 Dec 2022 / Consolidated, audited | Rs 793 cr | Rs 13.72 | n/a | n/a | Filing |
| Q2 FY23ended 30 Sep 2022 / Consolidated, audited | Rs 809 cr | Rs 14.37 | n/a | n/a | Filing |
| Q1 FY23ended 30 Jun 2022 / Consolidated, audited | Rs 785 cr | Rs 13.59 | n/a | n/a | Filing |
| Q4 FY22ended 31 Mar 2022 / Consolidated, audited | Rs 625 cr | Rs 10.98 | n/a | n/a | Filing |
| Q3 FY22ended 31 Dec 2021 / Consolidated, audited | Rs 601 cr | Rs 10.85 | n/a | n/a | Filing |
| Q2 FY22ended 30 Sep 2021 / Consolidated, audited | Rs 593 cr | Rs 12.65 | n/a | n/a | Filing |
| Q1 FY22ended 30 Jun 2021 / Consolidated, audited | Rs 606 cr | Rs 15.38 | n/a | n/a | Filing |
| Q4 FY21ended 31 Mar 2021 / Consolidated, audited | Rs 528 cr | Rs 13.02 | n/a | n/a | Filing |
| Q3 FY21ended 31 Dec 2020 / Consolidated, audited | Rs 548 cr | Rs 19.94 | n/a | n/a | Filing |
| Q2 FY21ended 30 Sep 2020 / Consolidated, audited | Rs 444 cr | Rs 9.55 | n/a | n/a | Filing |
| Q1 FY21ended 30 Jun 2020 / Consolidated, audited | Rs 522 cr | Rs 15.45 | n/a | n/a | Filing |
| Q4 FY20ended 31 Mar 2020 / Consolidated, audited | Rs 444 cr | Rs 6.30 | n/a | n/a | Filing |
| Q3 FY20ended 31 Dec 2019 / Consolidated, audited | Rs 429 cr | Rs 8.26 | n/a | n/a | Filing |
| Q2 FY20ended 30 Sep 2019 / Consolidated, audited | Rs 456 cr | Rs 11.67 | n/a | n/a | Filing |
| Q1 FY20ended 30 Jun 2019 / Consolidated, audited | Rs 446 cr | Rs 7.73 | n/a | n/a | Filing |
| Q4 FY19ended 31 Mar 2019 / Standalone, audited | Rs 379 cr | Rs 5.13 | n/a | n/a | Filing |
| Q3 FY19ended 31 Dec 2018 / Standalone, audited | Rs 352 cr | Rs 5.64 | n/a | n/a | Filing |
| Q2 FY19ended 30 Sep 2018 / Standalone, audited | Rs 404 cr | Rs 6.16 | n/a | n/a | Filing |
| Q1 FY19ended 30 Jun 2018 / Standalone, audited | Rs 366 cr | Rs 5.03 | n/a | n/a | Filing |
The official financialsFiled to 31 Mar 2026
JB Chemicals & Pharmaceuticals Limited's statements as filed: trailing twelve month P&L, the balance sheet, and the cash engine. Parsed from official XBRL, shown in crore.
Trailing twelve months, on filed quarters
Revenue (TTM)
4,148 crNet profit (TTM)
709 crEBIT (TTM)
958 crProfit before tax (TTM)
952 crNet margin (TTM)
17.1%Finance costs (TTM)
5.6 crBalance sheet, as filed 2026-03-31
Total assets
4,969 crShareholder equity
4,159 crTotal borrowings
0.0 crCash and equivalents
110 crInventory
683 crTrade receivables
781 crThe cash engine, latest filed year
Operating cash flow
704 crCapex
0.0 crFree cash flow
704 crInvesting flow
-586 crFinancing flow
-123 crAnnual trail, filed year over filed year
| Year | Revenue | Net profit | Equity | Borrowings | CFO |
|---|---|---|---|---|---|
| FY26 | 4,148 cr | 709 cr | 4,159 cr | 0.0 cr | 704 cr |
| FY25 | 3,918 cr | 660 cr | 3,433 cr | 13.8 cr | 902 cr |
| FY24 | 3,484 cr | 553 cr | 2,923 cr | 357 cr | 801 cr |
| FY23 | 3,149 cr | 410 cr | 2,480 cr | 548 cr | 626 cr |
| FY22 | 2,424 cr | 386 cr | 2,139 cr | 26.3 cr | 170 cr |
| FY21 | 2,043 cr | 449 cr | 1,813 cr | 32.6 cr | n/a |
Every figure is parsed from JB Chemicals & Pharmaceuticals Limited's official NSE XBRL filings by the BazaarBaazi earnings lab and shown in crore rupees. Display data, not a valuation model input.
Management on record22 earnings calls
Every JBCHEPHARM earnings call BazaarBaazi has indexed, latest 31 May 2026. Read management in its own words, straight from the filed transcript.
JB Chemicals & Pharmaceuticals Limited earnings calls on record
22 calls since 31 Aug 2021
Show 14 older calls
Each entry links to the transcript PDF the company filed with the exchange. Primary sources, in management's own words.
What changed2 disclosures
Every recent official filing from JB Chemicals & Pharmaceuticals Limited, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.
JB Chemicals & Pharmaceuticals Limited has filed 2 official disclosures recently. The most recent is a Earnings dated 31 Mar 2026.
Event Heat
50 / 100JB Chemicals & Pharmaceuticals Limited Q4 FY26 earnings result: weak
JB Chemicals & Pharmaceuticals Limited Q4 FY26 earnings result: insufficient
Event Heat is a dated net read of JB Chemicals & Pharmaceuticals Limited's last 180 days of official disclosures, balancing the constructive filings against the ones to watch. It is a signal from what the company has filed, not investment advice. Every line above links to its official exchange filing, and the full market desk is at the disclosures hub.
Key fundamentalsEditorial reference
The anchor data BazaarBaazi references when reading the JBCHEPHARM chart. Not a substitute for a registered research note.
| Ticker | JBCHEPHARM |
|---|---|
| Full name | JB Chemicals & Pharmaceuticals Limited |
| Sector | Healthcare |
| Index class | MID CAP |
| ISIN | INE572A01036 |
| Market-cap band | ~38,455 cr (indicative) |
| Last referenced level | Inside latest show |
| Last session move | Not referenced this cycle |
| Editorial line in | Systematic Read on 20 Jul 2026 |
| Aliases tracked | JBCHEPHARM |
Reference chartLevels in show
The daily frame the desk reads on JBCHEPHARM.
FAQ11 reader questions · AEO-eligible
The line on JBCHEPHARM, distilled and schema-marked for AI Overview, Perplexity, and reader search.
What is the JBCHEPHARM share price target for 2026?
BazaarBaazi does not publish a SEBI-registered price target on JBCHEPHARM. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 20 Jul 2026.
What is BazaarBaazi's Crack Score for JBCHEPHARM?
The BazaarBaazi Crack Score for JBCHEPHARM is 93 out of 100 as of 21 Jul 2026, a high conviction reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.
What is the F&O view on JBCHEPHARM?
Strike-level option inventory for JBCHEPHARM is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.
What sector is JBCHEPHARM in and which peers does BazaarBaazi track?
JBCHEPHARM sits in Healthcare (mid cap), indicative market cap ~38,455 cr (indicative), ISIN INE572A01036. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on JB Chemicals & Pharmaceuticals Limited: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
How often is the JBCHEPHARM view updated?
This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on JBCHEPHARM is bullish, published in Systematic Read on 20 Jul 2026.
Is JBCHEPHARM a qualifying setup on the BazaarBaazi scanner right now?
On the 2026-07-21 run of the 500-name BazaarBaazi setup scanner, JB Chemicals & Pharmaceuticals Limited sits in the Scanned tier with a setup score of 66/100 (technical 100, fundamental 20). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.
Where can I read JB Chemicals & Pharmaceuticals Limited's earnings call transcripts?
BazaarBaazi indexes 22 JBCHEPHARM earnings calls going back to 2021-08-31, latest 2026-05-31. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.
What was JB Chemicals & Pharmaceuticals Limited's Q4 FY26 net profit?
JB Chemicals & Pharmaceuticals Limited reported a net profit of Rs 101 cr for Q4 FY26 (the quarter ended 31 March 2026). That is -30.4% year on year. The figure is from the company's official NSE filing.
What was JB Chemicals & Pharmaceuticals Limited's Q4 FY26 revenue?
JB Chemicals & Pharmaceuticals Limited reported revenue of Rs 904 cr for Q4 FY26. That is -4.8% year on year. The figure is from the company's official NSE filing.
How does BazaarBaazi rate JB Chemicals & Pharmaceuticals Limited's Q4 FY26 result?
BazaarBaazi gives JB Chemicals & Pharmaceuticals Limited's Q4 FY26 result a Result Pulse of 20 out of 100, with a verdict of Weak. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.
What has JB Chemicals & Pharmaceuticals Ltd announced recently?
The most recent official filing on record for JB Chemicals & Pharmaceuticals Ltd is an earnings dated 31 Mar 2026. It is the company's own earnings disclosure to the exchange, and it links to that filing on the BazaarBaazi stock page rather than to any third-party summary.
Related stock views
The names BazaarBaazi reads alongside JBCHEPHARM, each a living view refreshed every end-of-day run.